Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jun;56(6):989-93.
doi: 10.1016/j.jaad.2006.12.017.

Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature

Nicole M Annest  1 , Marta J VanBeek, Christopher J Arpey, Duane C Whitaker
Affiliations
Review

Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature

Nicole M Annest et al. J Am Acad Dermatol. 2007 Jun.

Abstract

Background: Intralesional methotrexate (MTX) is an effective treatment for keratoacanthoma (KA).

Objective: We sought to systematically examine response rates and adverse events in KA treated with intralesional MTX.

Methods: All cases of KA treated with intralesional MTX at our institution from 1991 to 2006 were identified. A MEDLINE and PubMed search of cases of KA treated with intralesional MTX was also performed.

Results: In all, 38 cases of KA treated with intralesional MTX were identified: 18 from our institution and 20 from the literature. Intralesional MTX achieved resolution in 92%, requiring an average of 2.1 injections an average of 18 days apart. Adverse events were rare, with two reports of pancytopenia in patients with chronic renal failure.

Limitations: Use of single case reports, small series, and retrospective analysis are limitations.

Conclusion: Intralesional MTX is a useful nonsurgical therapy for the treatment of KA. Histologic diagnosis before initiation of treatment is preferred. A complete blood cell count at baseline and during treatment should be considered to monitor for potential cytopenia.

PubMed Disclaimer

Substances